Humacyte (NASDAQ:HUMA) Given "Buy" Rating at D. Boral Capital

Humacyte (NASDAQ:HUMA - Get Free Report)'s stock had its "buy" rating restated by analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $25.00 price target on the stock.

HUMA has been the topic of several other research reports. HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Humacyte in a research note on Wednesday, March 12th. Benchmark reissued a "buy" rating on shares of Humacyte in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Humacyte presently has a consensus rating of "Buy" and a consensus target price of $13.71.

Humacyte Price Performance

Shares of NASDAQ HUMA traded down $0.05 during midday trading on Wednesday, hitting $1.96. The stock had a trading volume of 11,968,972 shares, compared to its average volume of 3,333,918. Humacyte has a fifty-two week low of $1.76 and a fifty-two week high of $9.97. The firm has a market cap of $246.68 million, a P/E ratio of -1.46 and a beta of 1.36. The company's 50-day simple moving average is $3.61 and its 200 day simple moving average is $4.50.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07. Equities analysts expect that Humacyte will post -1.27 EPS for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. acquired a new stake in Humacyte during the 4th quarter worth approximately $50,000. Petros Family Wealth LLC acquired a new position in Humacyte during the 4th quarter worth about $50,000. Syon Capital LLC bought a new stake in shares of Humacyte in the 4th quarter valued at about $54,000. Brookstone Capital Management bought a new position in shares of Humacyte during the fourth quarter worth about $56,000. Finally, ACT Wealth Management LLC acquired a new position in Humacyte in the fourth quarter valued at $57,000. Institutional investors own 44.71% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.